Skip to Content
Merck
CN

Key Documents

View All Documentation

N3785

Nabilone

solid, ≥98% (HPLC)

Synonym(s):

LY-109514

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C24H36O3
CAS Number:
51022-71-0
Molecular Weight:
372.54
NACRES:
NA.77
PubChem Substance ID:
329818640
UNSPSC Code:
12352200
MDL number:
MFCD00941490
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

form

solid

drug control

USDEA Schedule II; stupéfiant (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada, kontrollierte Droge in Deutschland

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

color

white

solubility

DMSO: soluble ~18 mg/mL, H2O: insoluble

application(s)

forensics and toxicology
veterinary

shipped in

wet ice

storage temp.

2-8°C

SMILES string

CCCCCCC(C)(C)c1cc(O)c2[C@@H]3CC(=O)CC[C@H]3C(C)(C)Oc2c1

InChI

1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1

InChI key

GECBBEABIDMGGL-RTBURBONSA-N

Related Categories

Biochem/physiol Actions

CB1 and CB2 cannabinoid receptor agonist.

Features and Benefits

This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Legal Information

German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Repr. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000082248
071M4604V
087K4623
063K4619

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Roger G Pertwee
British journal of pharmacology, 156(3), 397-411 (2009-02-20)
Medicines that activate cannabinoid CB(1) and CB(2) receptor are already in the clinic. These are Cesamet (nabilone), Marinol (dronabinol; Delta(9)-tetrahydrocannabinol) and Sativex (Delta(9)-tetrahydrocannabinol with cannabidiol). The first two of these medicines can be prescribed to reduce chemotherapy-induced nausea and vomiting.
Mark A Ware et al.
Anesthesia and analgesia, 110(2), 604-610 (2009-12-17)
Sleep disorders affect many patients with chronic pain conditions. Cannabis has been reported by several patient populations to help sleep. We evaluated the safety and efficacy of nabilone, a synthetic cannabinoid, on sleep disturbance in fibromyalgia (FM), a disease characterized
Jarkko Kalliomäki et al.
Clinical and experimental pharmacology & physiology, 39(4), 336-342 (2012-01-12)
The aim of the present study was to investigate the effects of nabilone on capsaicin-induced pain and hyperalgesia, as well as on biomarkers of cannabinoid central nervous system (CNS) effects. A randomized, double-blind, placebo-controlled, crossover study was conducted in 30
Regulation of synthetic cannabinoids.
C Heather Ashton et al.
Lancet (London, England), 374(9701), 1595-1595 (2009-11-10)
Joshua A Lile et al.
Drug and alcohol dependence, 116(1-3), 86-92 (2011-01-14)
Agonist replacement treatment is a promising strategy to manage cannabis-use disorders. The aim of this study was to assess the combined effects of the synthetic cannabinoid agonist nabilone and Δ⁹-tetrahydrocannabinol (Δ⁹-THC) using drug-discrimination procedures, which are sensitive to drug interactions.
View All Related Papers

Global Trade Item Number

SKUGTIN
N3785-25MG04061832557519

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service